Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Posted by: The Sumaira Foundation in
Read MoreChoose Your Language:
Posted by: The Sumaira Foundation in
Read MorePosted by: The Sumaira Foundation in
Read MorePosted by: The Sumaira Foundation in
Read More